Impact of positive lymph nodes and RAI therapy on survival in N1b papillary thyroid carcinoma

被引:0
作者
Jian, Jie [1 ]
Wei, Meng [2 ]
Li, Xumei [1 ]
Xiong, Qian [3 ]
Xiang, Jiangming [2 ]
Zhao, Shengping [2 ]
Peng, Yuxi [4 ]
Huang, Jingjing [2 ]
机构
[1] Chongqing Changshou Dist Maternal & Child Hlth Hos, Dept Pathol, Chongqing, Peoples R China
[2] Chongqing Changshou Dist Maternal & Child Hlth Hos, Dept Surg, Chongqing, Peoples R China
[3] Yangzhou Univ, Jiangsu Prov Affiliated Hosp, Huaian Maternal & Child Hlth Care Ctr, Dept Pathol, Huaian, Peoples R China
[4] Boai Hosp Zhongshan, Dept Pathol, Zhongshan, Peoples R China
来源
FRONTIERS IN ENDOCRINOLOGY | 2025年 / 16卷
关键词
papillary thyroid carcinoma; positive lymph node; radioactive iodine; survival; SEER; RADIOACTIVE IODINE; CANCER; ASSOCIATION; MANAGEMENT; RISK;
D O I
10.3389/fendo.2025.1551075
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Patients with N1b papillary thyroid carcinoma (PTC) was associated with a worse prognosis. The prognostic role of positive lymph nodes (PLN) and whether postoperative radioactive iodine (RAI) therapy conferred a survival benefit were debatable issues in these patients. Methods: Data were drawn from the SEER database for PTC patients with clinical N1b disease diagnosed between 2004-2015. All patient underwent total thyroidectomy with or without RAI. Patients were categorized by age (>= 55 years and <55 years) and analyzed based on PLN. Propensity score matching (PSM) were used to balance characteristics between patients who did and did not receive RAI therapy. Overall survival (OS) was the primary outcome. Kaplan-Meier survival analysis and Cox analysis were performed. Results: A total of 4343 N1b PTC patients were included, with 884 patients aged >= 55 years and 3459 patients aged <55 years. In patients aged >= 55 years, the optimal PLN cutoff for risk stratification was 8. Those with PLN >= 9 had significantly lower 5-year (83.7% vs. 90.1%), 10-year (67.4% vs. 78.8%) and 15-year (50.3% vs. 59.5%) OS rates. After adjusting, the hazard ratio for death in the PLN >= 9 group increased by 30%. After PSM, in subgroup of aged >= 55 years and PLN >= 9, the survival benefit was notable in those received RAI therapy. In contrast, for patients aged >= 55 years and PLN <= 8 or aged <55 years, no survival difference was found between those received RAI and those not. Conclusions: In N1b PTC patients aged >= 55 years, PLN >= 9 predicted a poorer survival. Postoperative RAI therapy offered survival benefits for this subgroup.
引用
收藏
页数:9
相关论文
共 22 条
[1]   The Association Between Radioiodine Refractory in Papillary Thyroid Carcinoma, Sodium/Iodide Symporter Expression, and BRAFV600E Mutation [J].
Anekpuritanang, Tauangtham ;
Uataya, Maythad ;
Claimon, Apichaya ;
Laokulrath, Natthawadee ;
Pongsapich, Warut ;
Pithuksurachai, Paveena .
ONCOTARGETS AND THERAPY, 2021, 14 :3959-3969
[2]   Predictive Value of Clinical and Pathological Characteristics for Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma: A 16-year Retrospective Study [J].
Chai, Jinyan ;
Zhang, Ruiguo ;
Zheng, Wei ;
Zhang, Guizhi ;
Jia, Qiang ;
Tan, Jian ;
Meng, Zhaowei ;
Wang, Renfei .
FRONTIERS IN ENDOCRINOLOGY, 2022, 13
[3]   American Thyroid Association Guidelines and National Trends in Management of Papillary Thyroid Carcinoma [J].
Gordon, Alex J. ;
Dublin, Jared C. ;
Patel, Evan ;
Papazian, Michael ;
Chow, Michael S. ;
Persky, Michael J. ;
Jacobson, Adam S. ;
Patel, Kepal N. ;
Suh, Insoo ;
Morris, Luc G. T. ;
Givi, Babak .
JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2022, 148 (12) :1156-1163
[4]   2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer [J].
Haugen, Bryan R. ;
Alexander, Erik K. ;
Bible, Keith C. ;
Doherty, Gerard M. ;
Mandel, Susan J. ;
Nikiforov, Yuri E. ;
Pacini, Furio ;
Randolph, Gregory W. ;
Sawka, Anna M. ;
Schlumberger, Martin ;
Schuff, Kathryn G. ;
Sherman, Steven I. ;
Sosa, Julie Ann ;
Steward, David L. ;
Tuttle, R. Michael ;
Wartofsky, Leonard .
THYROID, 2016, 26 (01) :1-133
[5]   Central Lymph Node Ratio Predicts Recurrence in Patients with N1b Papillary Thyroid Carcinoma [J].
Kang, Il Ku ;
Kim, Kwangsoon ;
Park, Joonseon ;
Bae, Ja Seong ;
Kim, Jeong Soo .
CANCERS, 2022, 14 (15)
[6]   Modification of the eight-edition tumor-node-metastasis staging system with N1b for papillary thyroid carcinoma: A multi-institutional cohort study [J].
Kim, Mijin ;
Kim, Hee Kyung ;
Kim, Hye In ;
Kim, Eun Heui ;
Jeon, Mm Ji ;
Yi, Hyon-Seung ;
Kim, Eun Sook ;
Kim, Hosu ;
Kim, Tae Hyuk ;
Kim, Bo Hyun ;
Kim, Tae Yong ;
Kang, Ho-Cheol ;
Kim, Won Bae ;
Chung, Jae Hoon ;
Shon, Young Kee ;
Kim, Sun Wook ;
Kim, Won Gu .
ORAL ONCOLOGY, 2018, 86 :48-52
[7]   Radioactive iodine ablation may not decrease the risk of recurrence in intermediate-risk papillary thyroid carcinoma [J].
Kim, Seo Ki ;
Woo, Jung-Woo ;
Lee, Jun Ho ;
Park, Inhye ;
Choe, Jun-Ho ;
Kim, Jung-Han ;
Kim, Jee Soo .
ENDOCRINE-RELATED CANCER, 2016, 23 (05) :367-376
[8]   PROGNOSTIC VALUE OF LYMPH NODE UPTAKE ON PRETREATMENT F-18 FDG PET/CT IN PATIENTS WITH NIB PAPILLARY THYROID CARCINOMA [J].
Lee, Chang-Hee ;
Lee, Sang-Woo ;
Son, Seung Hyun ;
Hong, Chae Moon ;
Jeong, Ju Nye ;
Feong, Shin Young ;
Ahn, Byeong-Cheol ;
Lee, Jaetae .
ENDOCRINE PRACTICE, 2019, 25 (08) :787-793
[9]   Noninferior response in BRAFV600E mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy [J].
Li, Jiao ;
Liang, Jun ;
Zhao, Teng ;
Lin, Yansong .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 (06) :1034-1039
[10]   The Genetic Duet of BRAF V600E and TERT Promoter Mutations Robustly Predicts Loss of Radioiodine Avidity in Recurrent Papillary Thyroid Cancer [J].
Liu, Jiajun ;
Liu, Rengyun ;
Shen, Xiaopei ;
Zhu, Guangwu ;
Li, Biao ;
Xing, Mingzhao .
JOURNAL OF NUCLEAR MEDICINE, 2020, 61 (02) :177-182